Silence Therapeutics plc (OTCMKTS:SLNCF) Sees Significant Growth in Short Interest

Silence Therapeutics plc (OTCMKTS:SLNCF) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 2,350 shares, an increase of 351.9% from the August 15th total of 520 shares. Based on an average daily volume of 521 shares, the short-interest ratio is presently 4.5 days.

Silence Therapeutics Price Performance

Shares of OTCMKTS:SLNCF opened at $4.00 on Friday. The firm’s 50 day simple moving average is $3.00 and its 200-day simple moving average is $2.26. Silence Therapeutics has a one year low of $1.06 and a one year high of $5.99.

Silence Therapeutics Company Profile

Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.

The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.